Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Training Course Day 1 of 2
CMC Analytical, Comparability and Stability Studies
This course provides a comprehensive overview of the phase-specific requirements for CMC analytical characterization, comparability, release and stability of biotechnology products from the preclinical phase through clinical trials to commercialization and post-approval. Analytical considerations for a wide variety of biopharmaceuticals are discussed, including monoclonal antibodies, therapeutic proteins, gene therapy, vaccines, and complex products (e.g. antibody drug conjugates). Details are presented on establishing and maintaining product reference standards, designing successful comparability tests (including specifics for biosimilar studies), setting meaningful product specifications, conducting forced degradation studies, technology transfer and bridging changes in analytical methods and generating effective stability protocols. Critical elements of laboratory quality practices that significantly impact the reliability of test data from R&D through cGMP are illustrated.
Introduction to Biopharmaceutical Manufacturing
This course provides a fundamental understanding of biopharmaceutical manufacturing. Organized along the development path, the course will describe the activities necessary to bring a biopharmaceutical from discovery to market. Included in the course will be the analytical, quality and regulatory challenges as well as the technical activities required. The instructors will discuss how development activities integrate and the best practices for drug substance and drug product production. At the conclusion of the course the attendee will have learned the steps needed to develop and produce a safe and effective biopharmaceutical that meets industry and patient needs. Identified during the course will be how to implement QbD in development and communicating with regulatory agencies throughout development.
SYMPOSIUM 1 - Cell-Based Immunotherapies - From Concept to Commercialization
Cell-Based Immunotherapies - From Concept to Commercialization
SYMPOSIUM 2 - Continuous Processing
SYMPOSIUM 3 - On Time and within Budget: Successful Program Management of Biologics Development – Tools, Techniques and Lessons Learned
On Time and within Budget: Successful Program Management of Biologics Development – Tools, Techniques and Lessons Learned
Strong Program Management is critical to the successful completion of biologics programs. This workshop presents proven tools and methodologies while focusing on the idiosyncrasies of biotechnology. We will review the integration and management of R&D, CMC, preclinical and clinical programs from discovery to licensure/commercial launch. We will address partner and supplier management (CMOs, CROs…) as well as the securing and management of program funding (government and private equity).
Topics to be Covered:
SYMPOSIUM 4 - Modern CMC Regulatory Strategies and Insights - from Concept to Approval
Modern CMC Regulatory Strategies and Insights - from Concept to Approval
On average, it still takes in excess of 10 years to develop a new biopharmaceutical drug product. It is estimated that the cost of developing a new biopharmaceutical drug product, and taking into account the > 90% failure rate, is over $2 billion. Conscious of this, the modern viewpoint is looking at ways in which to reduce this overall time and cost element. One strategy is to impart an approach of ‘accelerated development’ which, if done sensibly, can present an attractive and viable option. Quality focused planning, e.g. facilitated by quality by design, can also be used to potentially ‘shave off’ time to approval, whilst maintaining all important quality and regulatory maneuverability. Although faster development is attractive, regulatory aspects, particularly regulatory CMC also needs to keep up pace - which presents a number of difficult challenges. Pinch points:
This session provides an overview of modern regulatory CMC strategies which may be selectively applied for a cross range of product classes (e.g. biopharmaceuticals, biologics, advanced therapy medicinal products, biosimilars, vaccines) and how this can be used in consideration for objectively reducing the overall time and cost. This ‘interactive’ session will focus on biopharmaceuticals, biologics, ATMPs, vaccines and biosimilars. Collective team discussions, whiteboard exemplification and work-throughs will be made on key topic points.
Topics to be Covered:
SYMPOSIUM 5 - Supply Chain Security and Transparency from Starting Materials to Patient
Supply Chain Security and Transparency from Starting Materials to Patient
Symposium Moderator and Opening Remarks
Introduction to Rx-360 and our Patient-Centric Work
Mark Paxton, CEO, Rx-360 International Pharmaceutical Supply Chain Consortium
Morning Session: Why Upstream Quality Matters
Supply Chain Mapping: Better Do it!
Rob Welsh, Vice President, Bioprocessing Segment Solutions, VWR and Rx-360 International Pharmaceutical Supply Chain; Consortium Board Member & Co-Chair of Supply Chain Security Steering Committee
Rx-360 Response to Supplier Qualification
Ben Mills, Pharmaceutical Technical Lead, British Standards Institution
What We Expect of Suppliers
Lucy Cabral, Head, Supplier Quality Management, Genentech, Inc.
Why Standardizing Quality Agreements and Supplier Assessment Questionnaires is Important
Rick Calabrese, Global Director of Corporate Quality Systems, Sartorius Stedim North America
Afternoon Session: Who are Your Trading Partners and Why?
Why Managing a Global Problem Cannot Be Solved Locally
Brian Johnson, Senior Director Supply Chain Security, Pfizer, Inc.
Amgen Efforts to Resolve Global Requirements
Tim Valko, Executive Director, US Supply Chain, Amgen, Inc.
Compliance with Good Distribution Practices: How Many Standards?
David Ulrich, QA Director - Supply Chain, Abbvie
Where is the Last Mile, and Why Do We Care?
David Bang, CEO LifeConEx, DHL Global Forwarding
Cargo Thefts: Oh Yeah, They Occur!
Brad Elrod, Director, Global Conveyance Security, Pfizer Pharmaceuticals
Sartorius UniQure Site Tour (RSVP required)
Sartorius UniQure Site Tour
Sartorius will be hosting a Site Tour to the UniQure Facility in Lexington, MA on Tuesday, October 4th. Buses will leave the BCEC at 1pm and will return 6pm. Please select the 'Sartorius UniQure Site Tour' option on the registration page if you would like to attend. All registrations are subject to approval.
uniQure, a leading fully integrated AAV-based gene therapy company and the manufacturer of the first EU approved gene therapy product Glybera, has graciously offered to share its cutting edge Boston area manufacturing facility through a tour at BPI supported by Sartorius Stedim Biotech. The innovative facility construction implemented a design build process in just 10 months and is capable of simultaneous multi-product production at BSL-2. Capabilities include cell bank and seed stock production, DS production, DP filling and final product packaging. The facility showcases single-use production scale rocking motion and stirred tank bioreactors up to 500L and a custom automated vial filling system. Please join us for an evening of cocktails and appetizers along with a facility overview and tour.
View the Lexington Site Layout at: https://lifesciences.knect365.com/bioprocessinternational/sartorius-uniqure-site-tour